, as a combination of sulfapyridine and 5-amino salicylic acid, with the assumption that the sulfonamide antibiotic would counter the presumed infective component, and the salicylate the pain and stiffness components of polyarthritis. Sulfasalazine is now used in RA, particularly as a component of 'triple therapy' (in combination with methotrexate and hydroxychloroquine), but is perhaps used most in the treatment of peripheral spondyloarthritis.
Methotrexate was developed in 1946, but its use in RA was first documented nearly 40 years later 4 . This drug was initially (during the 1980s) used particularly in patients with PsA, as the skin lesions of PsA responded very well. Only after methotrexate began to be used at higher dosages (up to 25 mg per week, in contrast to the initial dose of three times 2.5 mg per week) did the real potential of this drug for the treatment of RA emerge 5 . Nowadays, both glucocorticoids and methotrexate are considered the 'anchor drugs' in the treatment of RA 6 . In many other inflammatory RMDs, methotrexate has found its place as a potent immunosuppressive drug, often enabling a decrease in glucocorticoid dosage 7 . of connective tissues diseases (for example, systemic sclerosis (SSc)), in osteoarthritis (OA) and in fibromyalgia, for which effective drug treatments are frequently lacking. On the occasion of the 70th anniversary of EULAR
, the major rheumatologic association of physicians, scientists, health professionals and people with rheumatic and musculoskeletal diseases (RMDs) in Europe, it is timely to reflect on the past, the present and the future challenges in rheumatology.
years of treatment of RMDs

Pharmacological treatment
Pharmacologic therapeutics for RMDs have evolved remarkably over the past 70 years. In addition, the widespread adoption of strategies to treat inflammatory RMDs intensively and early in the disease course have led to substantial gains in efficacy, such that drug-free remission is becoming an attainable goal in the treatment of RA 
T I M E L I N E
Managing rheumatic and musculoskeletal diseases -past, present and future Abstract | Progress in rheumatology has been remarkable in the past 70 years, favourably affecting quality of life for people with rheumatic and musculoskeletal diseases. Therapeutics have advanced considerably in this period, from early developments such as the introduction of glucocorticoid therapy to the general use of methotrexate and other disease-modifying agents, followed by the advent of biologic DMARDs and, most recently, small-molecule signalling inhibitors. Novel strategies for the use of such agents have also transformed outcomes, as have multidisciplinary nonpharmacological approaches to the management of rheumatic musculoskeletal disease including surgery, physical therapy and occupational therapy. Breakthroughs in our understanding of disease pathogenesis, diagnostics and the use of 'big data' continue to drive the field forward. Critically, the patient is now at the centre of management strategies as well as the future research agenda.
A variety of other conventional synthetic DMARDs (csDMARDs), such as gold, d-penicillamine, auranofin and leflunomide, as well as the targeted synthetic DMARD ciclosporin also found their place in the treatment of RMDs, especially inflammatory arthropathies. For many years before the introduction of methotrexate, gold salts and sulfasalazine were the only available csDMARDs. Subsequently, leflunomide offered an alternative treatment for RA in cases where methotrexate was ineffective or contraindicated. This phase of RMD treatment was remarkable for the use of drugs with narrow therapeutic windows (the range of dosage offering therapeutic benefit without unacceptable toxicity), which were pervasive, dominating clinical practice, and which led, in turn, to a conservative approach to care, often marked by delays in the commencement of effective therapeutics to the long-term detriment of the patient. The observation that combinations of csDMARDs conferred additional benefits without necessarily increased toxicity was a seminal advance. Moreover, these agents were also used to establish the principle that early intervention was preferable and that targeted treatment goals could dramatically improve outcomes 8 . Biologic DMARDs. Biologic DMARDs, or 'biologics' , delivered a further step-change in the treatment of RMDs. TNF was identified as a therapeutic target by elegant research that 15 , and has become the treatment of last resort for many patients with OA of the hip and knee. Interestingly, although previously commonly used for patients with RA, the necessity for such interventions has become increasingly rare with improved medical treatment for this disease 16 . Interesting new developments in the surgical approach to resolving articular problems, especially in different phases of OA, include resurfacing operations, joint distraction to postpone total joint replacement for relatively young patients (45-60 years old) 17 , mesenchymal stem cell transplantation for localized (often traumatic) osteoarthritic cartilage lesions, and others 18 . Minimally invasive surgical methods are being developed for the future treatment of RMDs. , several 'science-driven practice paradigm shifts' have had an important influence on the management of patients with RMDs. Self-management programmes, now widely used, superceded information provision and 'patient education' . Bed rest and assisted range-of-motion exercises were previously acclaimed, but developed into the positive and intensive use of exercise and physical activity. Finally, instead of only biomedical assessment of disease activity, we have Outcome Measures in Rheumatology (OMERACT)-initiated definitions and applications of patient-reported outcome measures. Two 'evolutions in practice' were also recognized. Understanding of psychological factors has evolved from acceptance of 'the arthritic personality' to actively addressing the patient's depression, anxiety, coping skills, sense of control and confidence. In addition, the implementation of important rules for nurses and other health professionals, as supported by EULAR strategic plans, have improved the management of patients with RMDs 6 .
Patient involvement.
Patients clearly recognize that the evolution of research and scientific knowledge has ushered in a new era of treatment and has made remission possible for many people with RMDs led to the discovery of its role in pathogenesis, and to the use of anti-TNF therapy in patients with RA 9 . Subsequently, TNF inhibitors were used in patients with spondyloarthritides (AS and PsA), psoriasis and juvenile idiopathic arthritis 10 , providing critical proof-of-concept that targeting inflammatory processes and pathways -capitalizing on the exquisite specificity of monoclonal antibodies and other biotechnical developmentscould translate to clinical care. Beyond TNF inhibitors, biologics with other mechanisms of action (targeting cytokines such as IL-1, IL-6, IL-17 and IL-12/23, depleting B cells, or interfering with co-stimulatory molecules or intracellular signalling pathways) have followed and are generally effective in an increasing range of RMDs, including systemic autoimmune diseases, gout and osteoporosis 10 . The market for biologics was virtually non-existent in the 1990s, but has now grown to well over €100 billion per year globally 11 .
In the past few years, medications inhibiting the Janus kinase (JAK) pathways have supplemented the therapeutic armamentarium against RA. Randomized controlled trials in RA have demonstrated the efficacy of JAK inhibitors with acceptable safety, and tofacitinib became the first JAK inhibitor to be approved, in many countries, for the treatment of RA. Baricitinib, another JAK inhibitor, was approved by the European Medicines Agency for the treatment of patients with RA after failure of methotrexate [12] [13] [14] . organizations -has become a driving force in the past few decades. Improved dissemination of information and promotion of self-management to patients have been important breakthroughs in improving outcomes. Increased patient participation in research adds the patients' views, and contributes to successful study design as well as outcome dissemination and implementation. Finally, awareness is growing that shared decision-making leads to therapeutic gain 20 .
years of diagnostics in RMDs
The diagnosis of RMDs has changed substantially in the past 70 years, owing particularly to advances in laboratory analyses and imaging modalities. A timeline of these developments in rheumatology is presented in FIG. 2 and major advances are discussed in this section. . Thus, the 'LE factor' was identified as antinuclear antibodies (ANAs). DNA was identified as the antigen responsible, although numerous other autoantibodies specific for nuclear antigens present in salt-soluble extracts from calf thymus cells (termed extractable nuclear antigens) have subsequently been detected 28 . Another major breakthrough was the detection of anti-neutrophil cytoplasmic antibodies (ANCAs) in 1985 by van der Woude et al., which has greatly helped in the diagnosis and management of vasculitides 29 . rheumatoid factors, but modern tests use nephelometry or, ideally, an ELISA system, which can detect rheumatoid factors of various immunoglobulin isotypes. In 1964, Nienhuis and others reported a novel antibody specificity, which they called the anti-perinuclear factor (APF), that recognized keratohyalin granules in buccal mucosa cells (reviewed previously 22 ). Fifteen years later came the discovery of anti-keratin antibodies (AKA), which were RA-specific and reacted with keratinized tissues of the oesophagus and, interestingly, also with cells from human hair follicles. Filaggrin was described as being recognized by RA sera in 1993, and subsequently it was shown that both APF and AKA reacted with (pro) fillagrin proteins (present in the keratohyalin granules in terminally differentiated epidermal cells), causing them to benamed anti-filaggrin antibodies.
Laboratory analyses
A major breakthrough was the detection of peptidyl-arginine deiminase, the enzyme responsible for the citrullination of molecules -including fillagrin, but also many others such as vimentin, collagen and enolase -that might subsequently become (auto)immunogenic. Antibodies to these citrullinated molecules were termed anti-citrullinated protein antibodies (ACPAs). All these findings 22 led to new systems to detect ACPAs, including the anti-cyclic citrullinated peptide test and subsequently others such as the modified Figure 1 | A timeline summarizing the evolution of treatment for rheumatoid arthritis. Injectable gold salts were among the earliest treatments for rheumatoid arthritis (RA); an oral gold compound (auranofin) is also available. Glucocorticoids have been widely used in the treatment of RA since the 1950s, and methotrexate since the 1980s.The first TNF inhibitor, etanercept, was approved for use in RA in 1998; further anti-TNF agents (infliximab, adalimumab, certolizumab and golimumab) soon followed. Other biologic DMARDs include agents that target B cells (rituximab), co-stimulatory molecules (abatacept), IL-6 (tocilizumab, sarilumab) and IL-1 (anakinra). Apremilast is a PDE4 inhibitor. Tofacitinib is the first-in-class Janus kinase inhibitor for the treatment of RA, followed by baricitinib. csDMARD, conventional synthetic DMARD; tsDMARD, targeted synthetic DMARD. Besides autoantibodies, the detection of the association of HLA-B27 with AS in 1973 paved the way for the analysis of immunogenetics in rheumatic diseases. The discovery of the link between HLA-B27 and a large family of inflammatory rheumatic diseases was one of the seminal advances in rheumatology 30 . Genetic associations have subsequently been identified with many other rheumatic and musculoskeletal as well as non-rheumatic diseases.
Imaging techniques
Besides a laboratory work-up, imaging procedures are important tools in the diagnosis and monitoring of RMDs. Conventional X-rays were detected in 1895 by the subsequent Nobel laureate Wilhelm C. Röntgen, a German mechanical engineer, radiodensity patterns of a plane through the head", inspired by seeing an automated apparatus built to reject frostbitten fruits by detecting dehydrated portions 35 . In 1961, he described the basic concept of tomography 36 , which was later used by McLeod Cormack to develop the mathematics behind CT technology 37 . The development of a practical device for transverse axial scanning was due in large part to the work of Godfrey Newbold Hounsfield, who shared with Cormack the 1979 Nobel Prize in Physiology or Medicine for the development of CT. In rheumatology, this technique is used in many areas ranging from the assessment of lung involvement in systemic autoimmune diseases to the evaluation of crystal dispositions in gout (by use of dual-emission CT), and in the detection of finger joint erosions using micro CT. These scores enabled the assessment of structural damage in, for instance, RA, and guided the design of many modern trials to provide evidence that modern treatments halt structural disease progression.
CT scanning. In 1959, the neurologist William Oldendorf developed the idea of "scanning a head through a transmitted beam of X-rays, and being able to reconstruct the . Today, MRI scanning is a standard procedure in nearly all fields of RMDs, such as the assessment of cartilage and meniscus in the knee, imaging of the sacroiliac joints and the sensitive assessment of structural damage using the RA-MRI scoring system (RAMRIS) 39 .
Ultrasonography. Another important and safe imaging procedure employed by rheumatologists is ultrasonography 40 . In 1941, the Austrian neurologist Karl Theo Dussik first used ultrasonography to image the human body, demonstrating the ventricles of a human brain. Subsequently, in Glasgow, Ian Donald first applied this technique to diagnosis in an obstetric context. Arthrosonograpy was first used in the early and mid-1970s to detect Baker's cysts 41 . A major breakthrough was the utilization of ultrasonography to detect alterations in the hips of newborns by Graf in 1981 (REF. 42 ). In the 1980s, numerous standardized techniques were described to establish this imaging modality in all fields of orthopaedics, trauma surgery and rheumatology. Newer ultrasonography techniques include colour and power Doppler imaging, which provide colour maps of tissues that reflect vascularization and hence inflammation in soft tissue (such as synovial tissue). EULAR continues to have a major role in the development of ultrasonography around the world, notably with publishing the first guidelines for musculoskeletal ultrasonography in rheumatology in 2001 (REF. 43 ).
communication technologies to health care (digital medicine, or 'e-health'), for example with continuous electronic evaluation and processing of measures of disease activity, prompting semi-automated clinical decision-making in real time 48 . Health care systems, too, will need to evolve to ensure equitable access to therapeutics and other advances at manageable costs to patient and payer alike. Partnerships between health care professionals, oversight organizations (such as EULAR) and governments will need to be agile and responsive to the changing needs of an ageing population that is demanding ever more robust and positive health-related outcomes. Patients are already crucial to the decision-making process and will be increasingly so, both at the individual level and also in terms of policy design and implementation. EULAR is supporting educational projects in this direction.
Conclusions
Amidst the progress and change mentioned above, it remains vital that organizations such as EULAR provide intellectual and philosophical cohesion and ensure that the rights and well-being of people with RMDs remain at the centre of our ambitions. The possibilities for remarkable progress also carry the risk of misdirection and political minimization of the true effects of RMDs on the lives of patients. An algorithmic approach to treatment should not be allowed to replace the fundamental depth and care that is implicit in the relationship between health professionals and people with RMDs and that pervades our discipline. Such a caring art of rheumatology should remain our legacy to future generations. Nailfold capillaroscopy. Since the early descriptions by Maricq and LeRoy in 1973 of the utility of nailfold capillaroscopy in grading the severity of SSc 44 , this technique for microscopic analysis of the microcirculation has become a validated qualitative and quantitative method for early diagnosis, prediction of clinical complications and optimizing management of SSc, and has been widely used in SSc since the 1990s. Capillaroscopic analysis was included in the 2013 ACR-EULAR guidelines for the classification of SSc, substantially improving the sensitivity and specificity of the criteria 45 .
The future of rheumatology What does the future hold in rheumatology? Medical science is advancing at an unprecedented pace, capitalizing on remarkable developments in techniques with which to interrogate pathogenesis, phenotype, disease progression and the effects of comorbidities. Molecular methodologies can now dissect the genome, epigenome, transcriptome, metabolome and proteome with ever-greater clarity. The computational sciences are evident in all elements of practice and will increasingly be so. More and more, we will move to a system-based approach to discovery, dominated by 'big data' as well as in silico modelling of the pathways and diagnostics with the most potential for clinical application. This approach will, in turn, provide new insights into the pathogenesis and, ultimately, the causes of RMDs. In the future, RMDs will be treated progressively earlier in the disease process, and might be rationalized at the molecular level and classified according to molecular pathotype rather than by clinical phenotype. The role of the microbiota in RMDs is one example of how modern approaches can be used to study the interaction of the human system with the environment 46 . Thus, the precision medicine revolution -now well advanced in cancer therapeutics but only nascent in our field -will be embraced for RMDs 47 . Taken to its logical conclusion, this approach will facilitate the search for the means to prevent and cure diseases that are currently considered chronic and to require pharmacotherapy in perpetuity. And as effective prophylactic or preventive treatments emerge, research efforts will realign to focus on refractory disease states as they become the new 'chronic illnesses' in our discipline.
Computational science is also likely to influence our daily practice via the application of information and
